A Double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation.
Latest Information Update: 09 Jun 2021
Price :
$35 *
At a glance
- Drugs AZD 1305 (Primary)
- Indications Atrial fibrillation
- Focus Pharmacogenomic; Therapeutic Use
- 24 Mar 2012 Planned number of patients changed from 212 to 272 as reported by European Clinical Trials Database record.
- 23 Dec 2009 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 23 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.